Edison Investment Research - Sarine Technologies (U77) Leader in diamond manufacturing equipment

Report

Edison Investment Research

Leader in diamond manufacturing equipment

Sarine is an established leader in equipment and services for the diamond manufacturing industry (the so-called “midstream”) with its own proprietary technology. Through new products and services, the company has entered the higher value-add downstream retail segment of the industry, which is more than twice the size of its traditional midstream market and commands higher valuations. This potentially underpins attractive growth and share price prospects over the medium term. Investors looking for direct exposure to the diamond industry may find the stock of interest in its initial stages of entering new markets.

30/05/2017 12 EN

Underlying

Sarine Technologies

Sarin Technologies Ltd. develops, manufactures, markets and sells precision technology products for the processing of diamonds and gemstones. Co.'s products provide solutions for every stage of the rough diamond manufacturing process, from determining the optimal polished gem based on true dollar value, through laser cutting and shaping, to inline quality control of the faceting. Co. also aids in key aspects of the polished diamond trade - the grading of a diamond's Cut and its Light Performance and by providing tools that simplify the online trade and enhance the in-store buying experience.

See profile

IL0010927254 Singapore Exchange Israel

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

Sarine Technologies - Focus on cost savings and marketing efforts

As the midstream market continues to struggle, Sarine reported a net loss of US$1.4m in Q119 amid weaker scanning activity and lower margins on equipment sales. In this environment, the company is focusing on prudent cost management and further promotion of retail-oriented products (which remains a minor part of the business at just under 3% of Q119 group sales). Management has recently seen some initial signs of potential recovery in the number of scanned stones. The company retained a solid gross cash position of US$32.7m (vs US$28.9m at end-2018).

May 21, 2019 May 21, 2019 4 EN

Edison Investment Research

Sarine Technologies - Focus on cost savings and marketing efforts

May 15, 2019 May 15, 2019 4 EN

Edison Investment Research

Sarine Technologies - External factors remain challenging

Sarine continued to experience more muted midstream demand in Q418, both in terms of capital equipment sales and recurring revenues. At the same time, it has kept its operating expenses under control, which allowed it to post a 6.3% y-o-y improvement in operating profit in FY18. As sales and marketing initiatives intensify in 2019 while industry challenges persist, the company has decided to temporarily reduce its dividend policy to one US cent every six months (from 2 US cents before), which still translates into a solid dividend yield at c 5% on an annualised basis.

February 28, 2019 February 28, 2019 5 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

1h / 4m 1h / 4m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

21h / 6m 21h / 6m 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

21h / 18m 21h / 18m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Leader in diamond manufacturing equipment

Sarine Technologies - Focus on cost savings and marketing efforts

Sarine Technologies - Focus on cost savings and marketing efforts

Sarine Technologies - External factors remain challenging

discoverIE Group - FY24 EPS in line; good margin progress

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe